Chronic Lymphocytic Leukemia Clinical Trial

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Summary

The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to chlorambucil in patients with untreated Chronic Lymphocytic Leukemia.

View Full Description

Full Description

Chlorambucil, is currently approved for treatment of frontline leukemia-cll/" >chronic lymphocytic leukemia, especially, but not limited to the ailing and elderly patient population. Several other more aggressive treatment options are available (e.g. fludarabine), however they are not suitable for all CLL patients, especially the ailing and elderly, due to greater toxicity. Ofatumumab is effective with low toxicity. The addition of ofatumumab to chlorambucil offers potentially a more effective therapy, with limited toxicity. The objective of this study was to evaluate progression-free survival (PFS), overall response and overall survival in subjects with previously untreated CLL with ofatumumab added to chlorambucil versus chlorambucil.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

confirmed CLL diagnosis and active CLL requiring treatment
considered inappropriate for fludarabine-based therapy
not been treated for CLL before
fully active at a minimum or fully capable of selfcare and up and about more than 50% of waking hours
age 18yrs or older
signed written informed consent

Exclusion Criteria:

prior CLL therapy
abnormal/inadequate blood values, liver, and kidney function
certain heart problems, active or chronic infections, serious significant diseases, active autoimmune hemolytic anemia (AIHA) requiring treatment, other current cancer or within last 5 years
CLL transformation
CLL central nervous system involvement
current participation in other clinical study
inability to comply with the protocol activities
lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 3

Estimated Enrollment:

447

Study ID:

NCT00748189

Recruitment Status:

Terminated

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 146 Locations for this study

See Locations Near You

Novartis Investigative Site
Sedona Arizona, 86336, United States
Novartis Investigative Site
Tucson Arizona, 85704, United States
Novartis Investigative Site
Murrieta California, 92562, United States
Novartis Investigative Site
Aurora Colorado, 80012, United States
Novartis Investigative Site
Denver Colorado, 80204, United States
Novartis Investigative Site
Boca Raton Florida, 33486, United States
Novartis Investigative Site
New Port Richey Florida, 34655, United States
Novartis Investigative Site
Ocala Florida, 34471, United States
Novartis Investigative Site
Ocoee Florida, 34761, United States
Novartis Investigative Site
Marietta Georgia, 30060, United States
Novartis Investigative Site
Chicago Illinois, 60612, United States
Novartis Investigative Site
Indianapolis Indiana, 46227, United States
Novartis Investigative Site
Lee's Summit Missouri, 64064, United States
Novartis Investigative Site
Raleigh North Carolina, 27607, United States
Novartis Investigative Site
Abilene Texas, 79606, United States
Novartis Investigative Site
Arlington Texas, 76014, United States
Novartis Investigative Site
Austin Texas, 78731, United States
Novartis Investigative Site
Dallas Texas, 75230, United States
Novartis Investigative Site
Dallas Texas, 75231, United States
Novartis Investigative Site
Fort Worth Texas, 76104, United States
Novartis Investigative Site
Midland Texas, 79701, United States
Novartis Investigative Site
Odessa Texas, 79761, United States
Novartis Investigative Site
San Antonio Texas, 78217, United States
Novartis Investigative Site
San Antonio Texas, 78229, United States
Novartis Investigative Site
Tyler Texas, 75702, United States
Novartis Investigative Site
Waco Texas, 76712, United States
Novartis Investigative Site
Webster Texas, 77598, United States
Novartis Investigative Site
Seattle Washington, 98133, United States
Novartis Investigative Site
Vancouver Washington, 98684, United States
Novartis Investigative Site
Yakima Washington, 98902, United States
Novartis Investigative Site
Brugge , 8000, Belgium
Novartis Investigative Site
Bruxelles , 1200, Belgium
Novartis Investigative Site
Gent , 9000, Belgium
Novartis Investigative Site
Haine-Saint-Paul , 7100, Belgium
Novartis Investigative Site
Leuven , 3000, Belgium
Novartis Investigative Site
Porto Alegre Rio De Janeiro, 91350, Brazil
Novartis Investigative Site
Sao Paulo São Paulo, 05403, Brazil
Novartis Investigative Site
Sao Paulo São Paulo, 05651, Brazil
Novartis Investigative Site
Toronto Ontario, M4N 3, Canada
Novartis Investigative Site
Montreal Quebec, H3A1A, Canada
Novartis Investigative Site
Sherbrooke Quebec, J1H 5, Canada
Novartis Investigative Site
Brno , 625 0, Czechia
Novartis Investigative Site
Hradec Kralove , , Czechia
Novartis Investigative Site
Praha 10 , 100 3, Czechia
Novartis Investigative Site
Creteil , 94010, France
Novartis Investigative Site
Pierre Benite , 69495, France
Novartis Investigative Site
Karlsruhe Baden-Wuerttemberg, 76137, Germany
Novartis Investigative Site
Mannheim Baden-Wuerttemberg, 68161, Germany
Novartis Investigative Site
Stuttgart Baden-Wuerttemberg, 70190, Germany
Novartis Investigative Site
Ulm Baden-Wuerttemberg, 89081, Germany
Novartis Investigative Site
Erlangen Bayern, 91052, Germany
Novartis Investigative Site
Muenchen Bayern, 81241, Germany
Novartis Investigative Site
Regensburg Bayern, 93049, Germany
Novartis Investigative Site
Wuerzburg Bayern, 97070, Germany
Novartis Investigative Site
Frankfurt Hessen, 65929, Germany
Novartis Investigative Site
Kassel Hessen, 34119, Germany
Novartis Investigative Site
Hannover Niedersachsen, 30625, Germany
Novartis Investigative Site
Lehrte Niedersachsen, 31275, Germany
Novartis Investigative Site
Essen Nordrhein-Westfalen, 45122, Germany
Novartis Investigative Site
Koeln Nordrhein-Westfalen, 50937, Germany
Novartis Investigative Site
Moenchengladbach-Rheydt Nordrhein-Westfalen, 41239, Germany
Novartis Investigative Site
Muenster Nordrhein-Westfalen, 48149, Germany
Novartis Investigative Site
Saarbruecken Saarland, 66113, Germany
Novartis Investigative Site
Athens, , 11 52, Greece
Novartis Investigative Site
Thessaloniki , 564 2, Greece
Novartis Investigative Site
Thessaloniki , 57010, Greece
Novartis Investigative Site
Ahmedabad , 38000, India
Novartis Investigative Site
Bangalore , 56002, India
Novartis Investigative Site
Mumbai , 40001, India
Novartis Investigative Site
Mumbai , 40001, India
Novartis Investigative Site
New Delhi , 11002, India
Novartis Investigative Site
Pune , 41100, India
Novartis Investigative Site
Cork , , Ireland
Novartis Investigative Site
Dublin , 7, Ireland
Novartis Investigative Site
Galway , , Ireland
Novartis Investigative Site
James Street , 8, Ireland
Novartis Investigative Site
Limerick , , Ireland
Novartis Investigative Site
Tullamore , , Ireland
Novartis Investigative Site
Waterford , , Ireland
Novartis Investigative Site
Potenza Basilicata, 85100, Italy
Novartis Investigative Site
Napoli Campania, 80131, Italy
Novartis Investigative Site
Albano Laziale (Roma) Lazio, 00041, Italy
Novartis Investigative Site
Genova Liguria, 16132, Italy
Novartis Investigative Site
Brescia Lombardia, 25123, Italy
Novartis Investigative Site
Milano Lombardia, 20132, Italy
Novartis Investigative Site
Milano Lombardia, 20133, Italy
Novartis Investigative Site
Milano Lombardia, 20162, Italy
Novartis Investigative Site
Ascoli Piceno Marche, 63100, Italy
Novartis Investigative Site
Novara Piemonte, 28100, Italy
Novartis Investigative Site
Bari Puglia, 70124, Italy
Novartis Investigative Site
Palermo Sicilia, 90146, Italy
Novartis Investigative Site
Venezia - Mestre Veneto, 30174, Italy
Novartis Investigative Site
Vicenza Veneto, 36100, Italy
Novartis Investigative Site
Udine , 33100, Italy
Novartis Investigative Site
Amersfoort , 3818 , Netherlands
Novartis Investigative Site
Amsterdam , 1105 , Netherlands
Novartis Investigative Site
Den Haag , 2545 , Netherlands
Novartis Investigative Site
Groningen , 9713 , Netherlands
Novartis Investigative Site
Nijmegen , 6525 , Netherlands
Novartis Investigative Site
Rotterdam , 3015 , Netherlands
Novartis Investigative Site
Rotterdam , 3075 , Netherlands
Novartis Investigative Site
Bialystok , 15-27, Poland
Novartis Investigative Site
Chorzow , 41-50, Poland
Novartis Investigative Site
Lodz , 93-51, Poland
Novartis Investigative Site
Slupsk , 76-20, Poland
Novartis Investigative Site
Warszawa , 02-77, Poland
Novartis Investigative Site
Wroclaw , 50-36, Poland
Novartis Investigative Site
Moscow , 11547, Russian Federation
Novartis Investigative Site
Moscow , 12510, Russian Federation
Novartis Investigative Site
Moscow , 12516, Russian Federation
Novartis Investigative Site
Novosibirsk , 63005, Russian Federation
Novartis Investigative Site
St'Petersburg , 19102, Russian Federation
Novartis Investigative Site
St. Petersburg , 197 0, Russian Federation
Novartis Investigative Site
Barcelona , 08003, Spain
Novartis Investigative Site
Barcelona , 08025, Spain
Novartis Investigative Site
Hospitalet de Llobregat (Barcelona) , 08907, Spain
Novartis Investigative Site
Madrid , 28006, Spain
Novartis Investigative Site
Madrid , 28041, Spain
Novartis Investigative Site
Madrid , 28046, Spain
Novartis Investigative Site
Salamanca , 37007, Spain
Novartis Investigative Site
Valencia , 46010, Spain
Novartis Investigative Site
Lulea , SE-97, Sweden
Novartis Investigative Site
Stockholm , SE-14, Sweden
Novartis Investigative Site
Uppsala , SE-75, Sweden
Novartis Investigative Site
Plymouth Devon, PL6 8, United Kingdom
Novartis Investigative Site
Taunton Somerset, TA1 5, United Kingdom
Novartis Investigative Site
Sunderland Tyne, SR4 7, United Kingdom
Novartis Investigative Site
Bath , BA1 3, United Kingdom
Novartis Investigative Site
Belfast , BT9 7, United Kingdom
Novartis Investigative Site
Birmingham , B9 5S, United Kingdom
Novartis Investigative Site
Bournemouth , BH7 7, United Kingdom
Novartis Investigative Site
Bradford , BD9 6, United Kingdom
Novartis Investigative Site
Cambridge , CB2 0, United Kingdom
Novartis Investigative Site
Canterbury, Kent , , United Kingdom
Novartis Investigative Site
Carshalton , SM5 1, United Kingdom
Novartis Investigative Site
Cornwall , TR1 3, United Kingdom
Novartis Investigative Site
Dudley , DY1 2, United Kingdom
Novartis Investigative Site
Exeter , EX2 5, United Kingdom
Novartis Investigative Site
Glasgow , G12 O, United Kingdom
Novartis Investigative Site
Leeds , LS9 7, United Kingdom
Novartis Investigative Site
Liverpool , L7 8X, United Kingdom
Novartis Investigative Site
London , EC1M , United Kingdom
Novartis Investigative Site
London , SE5 9, United Kingdom
Novartis Investigative Site
Manchester , M13 9, United Kingdom
Novartis Investigative Site
Milton Keynes , MK6 5, United Kingdom
Novartis Investigative Site
Newcastle-upon-Tyne , NE7 7, United Kingdom
Novartis Investigative Site
Norwich , NR4 7, United Kingdom
Novartis Investigative Site
Oxford , OX3 7, United Kingdom
Novartis Investigative Site
Peterborough , PE3 9, United Kingdom
Novartis Investigative Site
Rhyl, Denbighshire , LL18 , United Kingdom
Novartis Investigative Site
Salford , M6 8H, United Kingdom
Novartis Investigative Site
Stoke on Trent , ST4 6, United Kingdom
Novartis Investigative Site
Swindon , SN3 6, United Kingdom
Novartis Investigative Site
Uxbridge , UB8 3, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 3

Estimated Enrollment:

447

Study ID:

NCT00748189

Recruitment Status:

Terminated

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider